RxGenesys Biotechnology Revenue and Competitors

American corporation driven by science and focused on the thorough development of wound healing and skin care solutions and compounds based on the novel microRNA and iPS (induced pluripotent stem cell) technologies. RxGenesys Biotech aims to revolutionize the standard ways to keep skin young and enhance the speed and quality of wound healing solutions through regenerative technology. Our ingredients are designed to maintain the skin cells’ natural balance and behavior, strengthen its natural protection against external elements and promote healthy and organized cell regeneration. RxGenesys makes available to the market the most innovative compounds derived from induced pluripotent stem cells and microRNA technologies evolved from the the stem researches awarded the Medicine Nobel Prize in 2006 and 2012 (Fire & Mello / RNA Interference - Gurdon & Yamanaka / Stem Cell Reprograming) Discovered during advanced research for cancer treatment, our iPS (induced Pluripotent Stem Cell) technology has shown remarkable properties in the treatment of aging skin and wound healing. This find led to the development or RxGenesys Skincare by plastic Surgeon Jeffrey Gibson MD and the creation of RxGenesys Biotech. RxGenesys has the unique capacity to harness the power of iPS technology and combine it with the most innovative ingredients in the market to create REAL solutions based on science for the cosmetic and wound healing industry